Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

References for PMC Articles for PubMed (Select 16168057)

1.

Peripheral neuropathy associated with capecitabine.

Saif MW, Wood TE, McGee PJ, Diasio RB.

Anticancer Drugs. 2004 Sep;15(8):767-71.

PMID:
15494638
2.

Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.

Leonard GD, Wagner MR, Quinn MG, Grem JL.

Anticancer Drugs. 2004 Aug;15(7):733-5.

PMID:
15269607
3.
4.

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators.

N Engl J Med. 2004 Jun 3;350(23):2343-51.

5.

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E.

J Clin Oncol. 2004 Jun 1;22(11):2084-91.

6.

Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.

Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK.

Muscle Nerve. 2004 Mar;29(3):387-92.

PMID:
14981738
7.

Cancer statistics, 2004.

Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ; American Cancer Society.

CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. Review.

PMID:
14974761
8.

Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.

Shields AF, Zalupski MM, Marshall JL, Meropol NJ.

Cancer. 2004 Feb 1;100(3):531-7.

9.

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR.

J Clin Oncol. 2004 Jan 1;22(1):23-30. Epub 2003 Dec 9.

10.

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A.

J Clin Oncol. 2004 Jan 15;22(2):229-37. Epub 2003 Dec 2.

11.

Oxaliplatin-safety profile: neurotoxicity.

Grothey A.

Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13. Review.

PMID:
14523789
12.

Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.

Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D, Cognetti F.

Ann Oncol. 2003 Sep;14(9):1378-82.

13.

Capecitabine-related neurotoxicity presenting as trismus.

Couch LS, Groteluschen DL, Stewart JA, Mulkerin DL.

Clin Colorectal Cancer. 2003 Aug;3(2):121-3.

PMID:
12952569
14.

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG.

J Clin Oncol. 2003 Jun 1;21(11):2059-69.

PMID:
12775730
15.

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D.

J Clin Oncol. 2003 Apr 1;21(7):1307-12.

PMID:
12663719
16.

Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.

Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E, Quasthoff S, Grosskreutz J, Adelsberger H.

Clin Colorectal Cancer. 2002 May;2(1):54-8.

PMID:
12453338
17.

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Gamelin E, Gamelin L, Bossi L, Quasthoff S.

Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33. Review.

PMID:
12422305
18.

Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.

Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G.

J Clin Oncol. 2002 Aug 15;20(16):3478-83.

PMID:
12177109
19.

Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid.

Gedlicka C, Scheithauer W, Schüll B, Kornek GV.

J Clin Oncol. 2002 Aug 1;20(15):3359-61. No abstract available.

PMID:
12149316
20.

Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).

Cascinu S, Graziano F, Ferraù F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R.

Ann Oncol. 2002 May;13(5):716-20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk